Brief: Nurix Licenses A Drug Discovery Program To Sanofi Targeting A Novel Transcription Factor For Autoimmune Diseases
02/04/2025 13:10
April 2 (Reuters) - Nurix Therapeutics Inc NRIX.O: NURIX LICENSES A DRUG DISCOVERY PROGRAM TO SANOFI TARGETING A NOVEL TRANSCRIPTION FACTOR FOR AUTOIMMUNE DISEASES NURIX THERAPEUTICS- RECEIVES $15 MILLION LICENSE EXTENSION FEE FROM SANOFI NURIX THERAPEUTICS- ELIGIBLE FOR ADDITIONAL $465 MILLION IN MILESTONES AND ROYALTIES Source text: ID:nGNXp0z2 Further company coverage: NRIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis